NCT02486042View on ClinicalTrials.gov

Omega-3 Long Chain Polyunsaturated Fatty Acid (LCPUFA) Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Retinopathy of Prematurity
Interventions
DRUG

Omegaven

Infants will receive nutritional supplementation with omega-3 fatty acids (omegaven).

DIETARY_SUPPLEMENT

Standard lipids (primarily omega-6 fatty acids)

Infants will receive nutritional supplementation with standard intralipid, composed primarily of omega-6 fatty acids.

Trial Locations (1)

92037

University of California, San Diego Jacobs Medical Center, La Jolla

All Listed Sponsors
collaborator

The Hartwell Foundation

OTHER

lead

University of California, San Diego

OTHER

NCT02486042 - Omega-3 Long Chain Polyunsaturated Fatty Acid (LCPUFA) Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity | Biotech Hunter | Biotech Hunter